William P Schiemann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2556519/publications.pdf

Version: 2024-02-01

79 papers	8,429 citations	57758 44 h-index	69250 77 g-index

80 all docs	80 docs citations	80 times ranked	11923 citing authors

#	Article	IF	Citations
1	Role of Transforming Growth Factor Î² in Human Disease. New England Journal of Medicine, 2000, 342, 1350-1358.	27.0	2,264
2	TGF-Î²-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nature Cell Biology, 2001, 3, 708-714.	10.3	332
3	Mechanisms of the epithelialâ€“mesenchymal transition by TGF-Î². Future Oncology, 2009, 5, 1145-1168.	2.4	290
4	TGF-Î² upregulates miR-181a expression to promote breast cancer metastasis. Journal of Clinical Investigation, 2013, 123, 150-163.	8.2	264
5	Src Phosphorylates Tyr284 in TGF-Î² Type II Receptor and Regulates TGF-Î² Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion. Cancer Research, 2007, 67, 3752-3758.	0.9	223
6	Transforming growth factor-Î² and the hallmarks of cancer. Cellular Signalling, 2011, 23, 951-962.	3.6	218
7	Î²3Integrin and Src facilitate transforming growth factor-Î² mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 2006, 8, R42.	5.0	216
8	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-Î² signaling. Journal of Clinical Investigation, 2009, 119, 2678-2690.	8.2	209
9	The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-Î² in Normal and Malignant Mammary Epithelial Cells. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 169-190.	2.7	202
10	Deconstructing the mechanisms and consequences of TGF-Î²-induced EMT during cancer progression. Cell and Tissue Research, 2012, 347, 85-101.	2.9	202
11	The TGF-Î² paradox in human cancer: an update. Future Oncology, 2009, 5, 259-271.	2.4	187
12	The relevance of the TGF-Î² Paradox to EMT-MET programs. Cancer Letters, 2013, 341, 30-40.	7.2	174
13	Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Molecular Biology of the Cell, 2011, 22, 2423-2435.	2.1	162
14	Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-Â through a PGE2-dependent mechanisms. Carcinogenesis, 2008, 29, 2227-2235.	2.8	153
15	STAT3 and epithelialâ€“mesenchymal transitions in carcinomas. Jak-stat, 2014, 3, e28975.	2.2	151
16	Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-Î² signaling and metastasis. Breast Cancer Research, 2009, 11, R68.	5.0	143
17	Context-specific Effects of Fibulin-5 (DANCE/EVEC) on Cell Proliferation, Motility, and Invasion. Journal of Biological Chemistry, 2002, 277, 27367-27377.	3.4	141
18	Silencing Î²3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2015, 75, 2316-2325.	0.9	135

#	Article	IF	Citations
19	Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-Â in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis, 2008, 29, 2243-2251.	2.8	132
20	A Deletion in the Gene for Transforming Growth Factor Î² Type I Receptor Abolishes Growth Regulation by Transforming Growth Factor Î² in a Cutaneous T-Cell Lymphoma. Blood, 1999, 94, 2854-2861.	1.4	123
21	Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy. Bioconjugate Chemistry, 2019, 30, 907-919.	3.6	121
22	Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway. Journal of Biological Chemistry, 2013, 288, 17954-17967.	3.4	118
23	Non-muscle myosin IIB is critical for nuclear translocation during 3D invasion. Journal of Cell Biology, 2015, 210, 583-594.	5.2	116
24	Cystatin C Antagonizes Transforming Growth Factor Î² Signaling in Normal and Cancer Cells. Molecular Cancer Research, 2004, 2, 183-195.	3.4	113
25	Noncanonical TGF-Î² Signaling During Mammary Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 127-146.	2.7	103
26	Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature Communications, 2019, 10, 3668.	12.8	103
27	Homeoprotein Six1 Increases TGF-Î² Type I Receptor and Converts TGF-Î² Signaling from Suppressive to Supportive for Tumor Growth. Cancer Research, 2010, 70, 10371-10380.	0.9	101
28	Epithelialâ€“Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Molecular Cancer Research, 2020, 18, 1257-1270.	3.4	86
29	Lysyl Oxidase Contributes to Mechanotransduction-Mediated Regulation of Transforming Growth Factor-Î² Signaling in Breast Cancer Cells. Neoplasia, 2011, 13, 406-IN2.	5.3	85
30	Targeted inactivation of Î²1 integrin induces Î²3 integrin switching, which drives breast cancer metastasis by TGF-Î². Molecular Biology of the Cell, 2013, 24, 3449-3459.	2.1	84
31	Role of transforming growth factor-Î² in cancer progression. Future Oncology, 2006, 2, 743-763.	2.4	81
32	Altered TAB1:IÎºB Kinase Interaction Promotes Transforming Growth Factor Î²â€“Mediated Nuclear Factor-ÎºB Activation during Breast Cancer Progression. Cancer Research, 2008, 68, 1462-1470.	0.9	81
33	Role of TGF-Î² and the Tumor Microenvironment During Mammary Tumorigenesis. Gene Expression, 2011, 15, 117-132.	1.2	81
34	Grb2 binding to Tyr284 in TÎ²R-II is essential for mammary tumor growth and metastasis stimulated by TGF-Î². Carcinogenesis, 2008, 29, 244-251.	2.8	74
35	The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence. Scientific Reports, 2017, 7, 12698.	3.3	73
36	The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene, 2019, 38, 2020-2041.	5.9	70

#	Article	IF	Citations
37	p130Cas Is Required for Mammary Tumor Growth and Transforming Growth Factor-Î²-mediated Metastasis through Regulation of Smad2/3 Activity. Journal of Biological Chemistry, 2009, 284, 34145-34156.	3.4	62
38	PGE2 receptor EP2 mediates the antagonistic effect of COXâ€2 on TGFâ€Î² signaling during mammary tumorigenesis. FASEB Journal, 2010, 24, 1105-1116.	0.5	62
39	Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression. Neoplasia, 2015, 17, 317-328.	5.3	58
40	Activated Abl kinase inhibits oncogenic transforming growth factorâ€Î² signaling and tumorigenesis in mammary tumors. FASEB Journal, 2009, 23, 4231-4243.	0.5	56
41	Upregulated WAVE3 expression is essential for TGF-Î²-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Research and Treatment, 2013, 142, 341-353.	2.5	54
42	Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Research, 2013, 15, R72.	5.0	52
43	Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1â€“Mediated Macrophage Infiltration. Cancer Research, 2017, 77, 5129-5141.	0.9	52
44	X-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-Î²-mediated Nuclear Factor-ÎºB Activation during Breast Cancer Progression. Journal of Biological Chemistry, 2009, 284, 21209-21217.	3.4	46
45	TGF-Î² stimulation of EMT programs elicits non-genomic ER-Î± activity and anti-estrogen resistance in breast cancer cells. Journal of Cancer Metastasis and Treatment, 2017, 3, 150.	0.8	43
46	Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor beta signaling. BMC Cell Biology, 2004, 5, 2.	3.0	37
47	Therapeutic opportunities for targeting microRNAs in cancer. Molecular and Cellular Therapies, 2014, 2, 30.	0.2	36
48	Î²3 Integrinâ€“EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Molecular Biology of the Cell, 2011, 22, 4288-4301.	2.1	34
49	Transforming Growth Factor-Î² Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2â€“Dependent Bladder Cancer Cell Migration and Invasion. American Journal of Pathology, 2016, 186, 1351-1360.	3.8	33
50	Telomerase in Cancer: Function, Regulation, and Clinical Translation. Cancers, 2022, 14, 808.	3.7	30
51	Transforming growth factor-Î² (TGF-Î²)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-Î² receptor. Cancer Detection and Prevention, 2004, 28, 57-64.	2.1	29
52	The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer. Oncotarget, 2017, 8, 104072-104089.	1.8	25
53	Autophagy in breast cancer metastatic dormancy: tumor suppressing or tumor promoting functions?. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	24
54	Targeted TGF-Î² chemotherapies: friend or foe in treating human malignancies?. Expert Review of Anticancer Therapy, 2007, 7, 609-611.	2.4	23

#	Article	IF	Citations
55	WAVE3-NFÎºB Interplay Is Essential for the Survival and Invasion of Cancer Cells. PLoS ONE, 2014, 9, e110627.	2.5	22
56	Effective treatment of cancer metastasis using a dual-ligand nanoparticle. PLoS ONE, 2019, 14, e0220474.	2.5	21
57	Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 320-329.	7.4	17
58	SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-ÎºB and Notch signaling. Science Signaling, 2021, 14, .	3.6	17
59	c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget, 2016, 7, 72777-72794.	1.8	17
60	SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness. Life Science Alliance, 2020, 3, e201900427.	2.8	17
61	Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1Î±-mediated angiogenesis. Jak-stat, 2014, 3, e1009276.	2.2	16
62	Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers. Cell Death and Disease, 2017, 8, e2899-e2899.	6.3	16
63	A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity. PLoS Biology, 2019, 17, e3000204.	5.6	15
64	Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 68.	3.0	14
65	Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples. Recent Patents on Biomarkers, 2016, 5, 93-100.	0.2	14
66	Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	10
67	Epigenetic plasticity in metastatic dormancy: mechanisms and therapeutic implications. Annals of Translational Medicine, 2020, 8, 903-903.	1.7	10
68	Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Management and Research, 2016, 8, 21.	1.9	9
69	lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing Î±6 Integrin/CD49f Expression in Breast Cancer Stem Cells. Molecular Cancer Research, 2021, 19, 2068-2080.	3.4	9
70	The lncRNA BORG: a novel inducer of TNBC metastasis, chemoresistance, and disease recurrence. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	9
71	Preclinical Development of the Class-Iâ€“Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 397-406.	4.1	8
72	Chemotherapeutic targeting of the TGF-Î² pathway in breast cancers. Breast Cancer Management, 2014, 3, 73-85.	0.2	6

#	Article	IF	Citations
73	The role of RNA processing and regulation in metastatic dormancy. Seminars in Cancer Biology, 2021, , .	9.6	5
74	Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Translational Cancer Research, 2016, 5, S226-S232.	1.0	5
75	Tipping the balance between good and evil: aberrant 14-3-3Î¶ expression drives oncogenic TGF-Î² signaling in metastatic breast cancers. Breast Cancer Research, 2015, 17, 92.	5.0	3
76	The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin. Stem Cell Investigation, 2017, 4, 44-44.	3.0	1
77	Introduction to this special issue â€œBreast Cancer Metastasisâ€. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	1
78	The Multifunctional Roles of TGF-Î² in Navigating the Metastatic Cascade. , 2013, , 169-187.		0
79	ECO/siRNA nanoparticles and breast cancer metastasis. Oncoscience, 2015, 2, 823-824.	2.2	0